Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function

Janna K Duong; Shaun S Kumar; Carl Michael James Kirkpatrick; Louise Greenup; Manit Arora; Toong C Lee; Peter Timmins; Garry G Graham; Timothy J Furlong; Jerry R Greenfield; Kenneth M Williams; Richard O Day

doi:10.1007/s40262-013-0046-9

Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function

Janna K Duong, Shaun S Kumar, Carl Michael James Kirkpatrick, Louise Greenup, Manit Arora, Toong C Lee, Peter Timmins, Garry G Graham, Timothy J Furlong, Jerry R Greenfield, Kenneth M Williams, Richard O Day

Centre for Medicine Use and Safety

Research output: Contribution to journal › Article › Research › peer-review

77 Citations (Scopus)

Abstract

The population model enabled doses of metformin to be simulated for each stage of renal function, to ensure the concentrations of metformin do not exceed 5 mg/l. However, the plasma concentrations of metformin at these dosage levels are still quite variable and monitoring metformin concentrations may be of value in individualising dosage. This study provides confirmatory data that metformin can be used, with appropriate dosage adjustment, in patients with renal impairment.

Original language	English
Pages (from-to)	373 - 384
Number of pages	12
Journal	Clinical Pharmacokinetics
Volume	52
DOIs	https://doi.org/10.1007/s40262-013-0046-9
Publication status	Published - 2013

Access to Document

10.1007/s40262-013-0046-9

RM sElocation

Cite this

Duong, J. K., Kumar, S. S., Kirkpatrick, C. M. J., Greenup, L., Arora, M., Lee, T. C., Timmins, P., Graham, G. G., Furlong, T. J., Greenfield, J. R., Williams, K. M., & Day, R. O. (2013). Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function. Clinical Pharmacokinetics, 52, 373 - 384. https://doi.org/10.1007/s40262-013-0046-9

Duong, Janna K ; Kumar, Shaun S ; Kirkpatrick, Carl Michael James ; Greenup, Louise ; Arora, Manit ; Lee, Toong C ; Timmins, Peter ; Graham, Garry G ; Furlong, Timothy J ; Greenfield, Jerry R ; Williams, Kenneth M ; Day, Richard O. / Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function. In: Clinical Pharmacokinetics. 2013 ; Vol. 52. pp. 373 - 384.

@article{04f4a3758c18494d816ccb47b20fc901,

title = "Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function",

abstract = "The population model enabled doses of metformin to be simulated for each stage of renal function, to ensure the concentrations of metformin do not exceed 5 mg/l. However, the plasma concentrations of metformin at these dosage levels are still quite variable and monitoring metformin concentrations may be of value in individualising dosage. This study provides confirmatory data that metformin can be used, with appropriate dosage adjustment, in patients with renal impairment.",

author = "Duong, {Janna K} and Kumar, {Shaun S} and Kirkpatrick, {Carl Michael James} and Louise Greenup and Manit Arora and Lee, {Toong C} and Peter Timmins and Graham, {Garry G} and Furlong, {Timothy J} and Greenfield, {Jerry R} and Williams, {Kenneth M} and Day, {Richard O}",

year = "2013",

doi = "10.1007/s40262-013-0046-9",

language = "English",

volume = "52",

pages = "373 -- 384",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Springer - Adis",

}

Duong, JK, Kumar, SS, Kirkpatrick, CMJ, Greenup, L, Arora, M, Lee, TC, Timmins, P, Graham, GG, Furlong, TJ, Greenfield, JR, Williams, KM & Day, RO 2013, 'Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function', Clinical Pharmacokinetics, vol. 52, pp. 373 - 384. https://doi.org/10.1007/s40262-013-0046-9

Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function. / Duong, Janna K; Kumar, Shaun S; Kirkpatrick, Carl Michael James; Greenup, Louise; Arora, Manit; Lee, Toong C; Timmins, Peter; Graham, Garry G; Furlong, Timothy J; Greenfield, Jerry R; Williams, Kenneth M; Day, Richard O.

In: Clinical Pharmacokinetics, Vol. 52, 2013, p. 373 - 384.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: Simulation of doses according to renal function

AU - Duong, Janna K

AU - Kumar, Shaun S

AU - Kirkpatrick, Carl Michael James

AU - Greenup, Louise

AU - Arora, Manit

AU - Lee, Toong C

AU - Timmins, Peter

AU - Graham, Garry G

AU - Furlong, Timothy J

AU - Greenfield, Jerry R

AU - Williams, Kenneth M

AU - Day, Richard O

PY - 2013

Y1 - 2013

N2 - The population model enabled doses of metformin to be simulated for each stage of renal function, to ensure the concentrations of metformin do not exceed 5 mg/l. However, the plasma concentrations of metformin at these dosage levels are still quite variable and monitoring metformin concentrations may be of value in individualising dosage. This study provides confirmatory data that metformin can be used, with appropriate dosage adjustment, in patients with renal impairment.

AB - The population model enabled doses of metformin to be simulated for each stage of renal function, to ensure the concentrations of metformin do not exceed 5 mg/l. However, the plasma concentrations of metformin at these dosage levels are still quite variable and monitoring metformin concentrations may be of value in individualising dosage. This study provides confirmatory data that metformin can be used, with appropriate dosage adjustment, in patients with renal impairment.

UR - http://download.springer.com/static/pdf/270/art%253A10.1007%252Fs40262-013-0046-9.pdf?auth66=1381274303_5ff013b6d25554bc01e56a6c3609c6f9&ext=.pdf

U2 - 10.1007/s40262-013-0046-9

DO - 10.1007/s40262-013-0046-9

M3 - Article

VL - 52

SP - 373

EP - 384

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

ER -